Thyroid parameters | Whole group | UsGoiter | UsNonGoiter | p-value |
---|---|---|---|---|
Number of patients (N; %) | N = 115 | 44 (38.3) | 71 (61.7) | |
Family history of thyroid disorders (n/N; %) | 14/115 (12.2) | 7/44 (15.9) | 7/71 (9.8) | .76 |
Cancer | 1/115 (0.9) | 1/7 (14.3) | 0 | NA |
Clinical evaluation | ||||
Goiter (n/N; %) | 19/115 (16.5) | 19/44 (43.2) | 0 | <.001 |
Nodule (n/N; %) | 22/115 (19.1) | 12/44 (27.3) | 10/71 (14.1) | <.001 |
Ultrasound evaluation | ||||
Thyroid volume (mean ± SD, mL) | 22.9 ± 15.0 | 33.4 ± 25.2 | 12.2 ± 4.5 | <.001 |
Female ♀ (mean ± SD, mL) | 19.5 ± 19.3 | 30.8 ± 26.5 | 11.9 ± 3.5 | <.001 |
Male ♂ (mean ± SD, mL) | 22.2 ± 19.1 | 37.6 ± 23.1 | 12.7 ± 5.8 | <.001 |
< 45 years old (mean +/- SD) | 18.3 ± 12.3 | 28.6 ± 14.5 | 12.4 ± 4.8 | .015 |
> 45 years old (mean +/- SD) | 23.3 ± 25.0 | 38.1 ± 32.3 | 11.9 ± 4.2 | .003 |
UsNodule > 5 mm (TIRADS) (n/N; %) | 70/115 (60.9) | 36/44 (81.8) | 34/71 (47.9) | .0006 |
2 | 18/70 (25.7) | 11/36 (30.6) | 7/34 (20.6) | |
3 | 23/70 (32.8) | 9/36 (25) | 14/34 (41.2) | |
4 (4A and 4B) | 16/70 (22.9) | 7/36 (19.4) | 9/34 (26.5) | |
5 | 4/70 (5.7) | 2/36 (5.6) | 2/34 (5.9) | |
Missing data | 9/70 (12.9) | 7/36 (19.4) | 2/34 (5.9) | |
FNAC – Bethesda (22/116 FNAC) | 22/70 (31.4) | 13/36 (36.1) | 9/34 (26.5) | .03 |
1} Non-diagnostic | 5/22 (22.8) | 4/13 (30.8) | 1/9 (11.1) | |
2} Benign: 0–3% of malignancy | 11/22 (50.0) | 8/13 (61.5) | 3/9 (23.1) | |
3 and 4} 5–30% of malignancy | 3/22 (13.6) | 0 | 3/9 (23.1) | |
5 and 6} 60–99% of malignancy | 3/22 (13.6) | 1/13 (7.7) | 2/9 (15.4) | |
Biological evaluation | ||||
TSH (mean ± SD; μIU/mL) | 1.7 ± 1.2 | 1.3 ± 0.9 | 2.0 ± 1.2 | <.001 |
< 0.4 (n/N; %) | 9/115 (7.8) | 5/44 (11.4) | 4/71 (5.6) | |
0.4–3.6 (n/N; %) | 92/115 (80.0) | 34/44 (77.3) | 58/71 (81.7) | |
> 3.6 (n/N; %) | 15/115 (13.0) | 6/44 (13.6) | 9/71 (12.7) | .74 |
FT4 (mean ± SD; ng/dL) | 0.9 ± 0.3 | 0.9 ± 0.3 | 0.8 ± 0.2 | .01 |
FT3 (mean ± SD; pg/mL) | 3.4 ± 0.6 | 3.4 ± 0.6 | 3.4 ± 0.5 | .77 |
Anti-TPO Antibodies (n/N; %; IU/L) | .51 | |||
Negative | 52/115 (45.2) | 23/44 (52.3) | 29/71 (40.8) | |
Positive | 52/115 (45.2) | 19/44 (43.2) | 33/71 (46.5) | |
Missing data | 12/115 (10.4) | 3/44 (6.8) | 9/71 (21.9) | |
Thyroid cancer (n/N; %) | 9/115 (7.8) | 8/44 (18.2) | 1/71 (1.4) | .002 |
Recurrence (clinical and US scan) | 0 | 0 | 0 | |
Rise of thyroglobulin | 1/9 (11.1) | 1/8 (12.5) | 0 | |
Death | 0 | 0 | 0 | |
Treatment (n/N; %) | NA | |||
Total thyroidectomy – indications (n/N; %) | 16/115 (13.9) | 11/44 (25) | 5/71 (7.1) | |
For goiter (compression, aesthetic issues) | 10/16 (62.5) | 10/11 (91) | 0/5 | |
For suspicious nodule | 6/16 (37.5) | 1/11 (9) | 5/5 (100) | |
Radioiodine therapy for carcinoma | 3/9 (33.3) | 2/44 (4.5) | 1/71 (1.4) | |
LT4 Therapy | 23/115 (20) | 12/44 (27.3) | 11/71 (15.5) |